Milestone Pharmaceuticals Stock Forum

$Milestone Pharmaceuticals (MIST.US)$
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China
MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced its licensing partner, Ji Xing Pharmaceuticals Ltd, released positive topline re...

$Milestone Pharmaceuticals (MIST.US)$
Rodman & Renshaw Initiates Coverage On Milestone Pharmaceuticals with Buy Rating, Announces Price Target of $9

$Milestone Pharmaceuticals (MIST.US)$
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™
Milestone Pharmaceuticals announced the FDA's acceptance of its New Drug Application for CARDAMYST, an etripamil nasal spray intended for managing paroxysmal supraventricular tachycardia (PSVT). This milestone occurred on May 26, 2024, with a Prescription Drug User Fee Act (PDUFA) target date set for ten months later. The clinical trial program for CARDAMYST is the l...

$Milestone Pharmaceuticals (MIST.US)$
NEWS
Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024

$Milestone Pharmaceuticals (MIST.US)$ 👀👀

RECAP
S&P 500 Approaches All-Time High
US stocks rose, with the $S&P 500 Index (.SPX.US)$ approaching its all-time, high as optimism over potential interest rate cuts next year continued to fuel positive sentiment on the last trading week of the year.
The S&P 500 closed 0.42% higher at 4,774.75 on the first day of the holiday-shortened trading week. The $Nasdaq Composite Index (.IXIC.US)$ gained 0.5% to 15,074.57, while the $Dow Jones Industrial Average (.DJI.US)$ added 0.4...

$Milestone Pharmaceuticals (MIST.US)$ Milestone Pharmaceuticals Received An FDA Refusal To File Letter For The New Drug Application For Self-administered Etripamil Nasal Spray For Paroxysmal Supraventricular Tachycardia

$Milestone Pharmaceuticals (MIST.US)$ Milestone Pharmaceuticals Reports Submission Of New Drug Application To FDA For Etripamil

$Progressive (PGR.US)$ initiated at equal-weight by Morgan Stanley, announced target price at $135.00.
$Lemonade (LMND.US)$ initiated at underweight by Morgan Stanley, announced targe price at $14.00.
$Baidu (BIDU.US)$ was upgraded by Morgan Stanley from equal-weight to overweight, increased target price from $160.00 to $190.00.
$Philip Morris International (PM.US)$ was upgraded by Citigroup from neutral to buy, increased target price from $10...